RSS

heart failure

Healthcare solutions provider, Novartis, has announced new data demonstrating that its twice-a-day medicine, Entresto (sacubitril/valsartan) can be initiated early and safely in hospitalised patients after an acute heart failure episode. Read more

News

Pharmacosmos’ initiates first hard endpoint randomised controlled trial looking at the effect of intravenous (IV) iron in chronic heart failure (CHF) Read more

News

The heart failure market is set to rise by £5.8bn ($8.6bn) within the next century, according to GlobalData Read more

News

Novartis’ Entresto has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of heart failure Read more

News

The European Commission (EC) has approved Novartis’ Entresto (sacubitril/valsartan) for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF) Read more

News